|
|
 Previous Article | Table of Contents | Next Article 
Combined Arsenic and Retinoic Acid Treatment Enhances
Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells
Maurizio Giannì,
Marcel H.M. Koken,
Mounira K. Chelbi-Alix,
Gérard Benoit,
Michel Lanotte,
Zhu Chen, and
Hugues de Thé
From the Centre National de la Recherche Scientifique Unité
Propre de Recherche 9051, Laboratoire associé au Comité de
Paris de la Ligue Contre le Cancer, UIH, Université Paris VII,
Service de Biochimie B, Hôpital St Louis, Paris; INSERM
Unité 496, Hôpital St Louis, Paris, France; Shanghai
Institute of Hematology, Rui-Jin Hospital, Shanghai, China.
In the acute promyelocytic leukemia (APL) cell line NB4, as well as
in APL patients' cells, arsenic trioxide
(As2O3) leads to incomplete cell maturation,
induction of apoptosis, as well as to the degradation of the oncogenic
PML/RAR fusion protein. We have isolated an arsenic-resistant NB4
subline (NB4-AsR), which fails to undergo apoptosis, but
maintains the partial differentiation response to this drug. When grown
in the presence of As2O3, NB4-AsR
cells degrade PML/RAR, slightly differentiate, and become more sensitive to serum deprivation-induced apoptosis. Similarly, in RA-resistant NB4-R1 cells, RA induced a significant PML/RAR
degradation and yet failed to induce cell maturation. Thus,
As2O3- or retinoic acid (RA)-induced PML/RAR
degradation may be a prerequisite, but is not sufficient for the full
differentiative/apoptotic response to these drugs. Strikingly,
RA-triggered differentiation and apoptosis were greatly accelerated in
As2O3-treated NB4-AsR cells. The
synergism between these two agents in this setting could provide an
experimental basis for combined or sequential RA/As2O3 therapies.
Blood, Vol. 91 No. 11 (June 1), 1998:
pp. 4300-4310
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Hu, Y.-F. Liu, C.-F. Wu, F. Xu, Z.-X. Shen, Y.-M. Zhu, J.-M. Li, W. Tang, W.-L. Zhao, W. Wu, et al.
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
PNAS,
March 3, 2009;
106(9):
3342 - 3347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.-B. Zhou, J. Zhang, Z.-Y. Wang, S.-J. Chen, and Z. Chen
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy
Phil Trans R Soc B,
June 29, 2007;
362(1482):
959 - 971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kitareewan, B. D. Roebuck, E. Demidenko, R. D. Sloboda, and E. Dmitrovsky
Lysosomes and Trivalent Arsenic Treatment in Acute Promyelocytic Leukemia
J Natl Cancer Inst,
January 3, 2007;
99(1):
41 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ozpolat, U. Akar, M. Steiner, I. Zorrilla-Calancha, M. Tirado-Gomez, N. Colburn, M. Danilenko, S. Kornblau, and G. Lopez Berestein
Programmed Cell Death-4 Tumor Suppressor Protein Contributes to Retinoic Acid-Induced Terminal Granulocytic Differentiation of Human Myeloid Leukemia Cells
Mol. Cancer Res.,
January 1, 2007;
5(1):
95 - 108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Zykova, F. Zhu, C. Lu, L. Higgins, Y. Tatsumi, Y. Abe, A. M. Bode, and Z. Dong
Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma Cells
Clin. Cancer Res.,
December 1, 2006;
12(23):
6884 - 6893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Karlsson, A. Edsjo, S. Pahlman, and H. M. Pettersson
Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia
Mol. Cancer Ther.,
July 1, 2005;
4(7):
1128 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Douer and M. S. Tallman
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
J. Clin. Oncol.,
April 1, 2005;
23(10):
2396 - 2410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kamashev, D. Vitoux, and H. de The
PML-RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation
J. Exp. Med.,
April 19, 2004;
199(8):
1163 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z.-X. Shen, Z.-Z. Shi, J. Fang, B.-W. Gu, J.-M. Li, Y.-M. Zhu, J.-Y. Shi, P.-Z. Zheng, H. Yan, Y.-F. Liu, et al.
Inaugural Article: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
PNAS,
April 13, 2004;
101(15):
5328 - 5335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Raffoux, P. Rousselot, J. Poupon, M.-T. Daniel, B. Cassinat, R. Delarue, A.-L. Taksin, D. Rea, A. Buzyn, A. Tibi, et al.
Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia
J. Clin. Oncol.,
June 15, 2003;
21(12):
2326 - 2334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Jing, L. Xia, and S. Waxman
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia
Blood,
July 18, 2002;
100(3):
1008 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-C. Zhou, S. H. Kim, W. Ding, C. Schultz, R. P. Warrell Jr, and R. E. Gallagher
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo
Blood,
February 15, 2002;
99(4):
1356 - 1363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Zhu, J.-W. Zhang, H.-Q. Zhu, Y.-L. Shen, M. Flexor, P.-M. Jia, Y. Yu, X. Cai, S. Waxman, M. Lanotte, et al.
Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk
Blood,
February 1, 2002;
99(3):
1014 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-H. Hong, Z. Yang, and M. L. Privalsky
Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor {alpha} Oncoprotein Found in Human Acute Promyelocytic Leukemia
Mol. Cell. Biol.,
November 1, 2001;
21(21):
7172 - 7182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sordet, C. Rebe, I. Leroy, J.-M. Bruey, C. Garrido, C. Miguet, G. Lizard, S. Plenchette, L. Corcos, and E. Solary
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
Blood,
June 15, 2001;
97(12):
3931 - 3940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Jing, L. Wang, L. Xia, G.-q. Chen, Z. Chen, W. H. Miller, and S. Waxman
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
Blood,
January 1, 2001;
97(1):
264 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rego, L.-Z. He, R. P. Warrell Jr., Z.-G. Wang, and P. P. Pandolfi
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
PNAS,
August 17, 2000;
(2000)
180290497.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. J. Roboz, S. Dias, G. Lam, W. J. Lane, S. L. Soignet, R. P. Warrell Jr, and S. Rafii
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
Blood,
August 15, 2000;
96(4):
1525 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Puccetti, S. Güller, A. Orleth, N. Brüggenolte, D. Hoelzer, O. G. Ottmann, and M. Ruthardt
BCR-ABL Mediates Arsenic Trioxide-induced Apoptosis Independently of Its Aberrant Kinase Activity
Cancer Res.,
July 1, 2000;
60(13):
3409 - 3413.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Zhu, M. Gianni, E. Kopf, N. Honore, M. Chelbi-Alix, M. Koken, F. Quignon, C. Rochette-Egly, and H. de The
Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha ) and oncogenic RARalpha fusion proteins
PNAS,
December 21, 1999;
96(26):
14807 - 14812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Niu, H. Yan, T. Yu, H.-P. Sun, J.-X. Liu, X.-S. Li, W. Wu, F.-Q. Zhang, Y. Chen, L. Zhou, et al.
Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients
Blood,
November 15, 1999;
94(10):
3315 - 3324.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Naoe, K. Kitamura;, M. Fanelli, and P. G. Pelicci
Relationship Between Degradation of PML-RARalpha and Differentiation
Blood,
August 15, 1999;
94(4):
1478 - 1479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Sternsdorf, E. Puccetti, K. Jensen, D. Hoelzer, H. Will, O. G. Ottmann, and M. Ruthardt
PIC-1/SUMO-1-Modified PML-Retinoic Acid Receptor alpha Mediates Arsenic Trioxide-Induced Apoptosis in Acute Promyelocytic Leukemia
Mol. Cell. Biol.,
July 1, 1999;
19(7):
5170 - 5178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-R. Gurr, D.-T. Bau, F. Liu, S. Lynn, and K.-Y. Jan
Dithiothreitol Enhances Arsenic Trioxide-Induced Apoptosis in NB4 Cells
Mol. Pharmacol.,
July 1, 1999;
56(1):
102 - 109.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Melnick and J. D. Licht
Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
Blood,
May 15, 1999;
93(10):
3167 - 3215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kroemer and H. de The
Arsenic Trioxide, a Novel Mitochondriotoxic Anticancer Agent?
J Natl Cancer Inst,
May 5, 1999;
91(9):
743 - 745.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-H. Zhu, Y.-L. Shen, Y.-k. Jing, X. Cai, P.-M. Jia, Y. Huang, W. Tang, G.-Y. Shi, Y.-P. Sun, J. Dai, et al.
Apoptosis and Growth Inhibition in Malignant Lymphocytes After Treatment With Arsenic Trioxide at Clinically Achievable Concentrations
J Natl Cancer Inst,
May 5, 1999;
91(9):
772 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Lallemand-Breitenbach, M.-C. Guillemin, A. Janin, M.-T. Daniel, L. Degos, S. C. Kogan, J. Michael Bishop, and H. de The
Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia
J. Exp. Med.,
April 5, 1999;
189(7):
1043 - 1052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tamm, G. Paternostro, J. M. Zapata, M. E. Conrad, R. P. Warrell, and P. P. Pandolfi
Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
N. Engl. J. Med.,
April 1, 1999;
340(13):
1043 - 1045.
[Full Text]
|
|
|
|
|
|
|
L. Mologni, I. Ponzanelli, F. Bresciani, G. Sardiello, D. Bergamaschi, M. Gianni, U. Reichert, A. Rambaldi, M. Terao, and E. Garattini
The Novel Synthetic Retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene Carboxylic Acid (CD437) Causes Apoptosis in Acute Promyelocytic Leukemia Cells Through Rapid Activation of Caspases
Blood,
February 1, 1999;
93(3):
1045 - 1061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Gallagher
Arsenic -- New Life for an Old Potion
N. Engl. J. Med.,
November 5, 1998;
339(19):
1389 - 1391.
[Full Text]
|
|
|
|
|
|
|
E. M. Rego, L.-Z. He, R. P. Warrell Jr., Z.-G. Wang, and P. P. Pandolfi
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
PNAS,
August 29, 2000;
97(18):
10173 - 10178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
